$IMRN News

Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00

Immuron shares are trading higher after the company reported a year-over-year increase in its Q3 sales results.

Immuron shares are trading higher after the company reported a year-over-year increase in its Q3 sales results.

Immuron Double Digit 3Q Sales Growth

Immuron Reports Q3 Sales A$1.5M, Up 16% YoY

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target

Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference

Immuron Reports HY26 Results and Strategic Reset

Immuron H1 EPS $(0.01), Same YoY, Sales $4.184M Up From $3.994M YoY

Immuron Reports HY26 Results With AUD$4.2M Sales, AUD$10M Cash, Strategic Reset And FDA IND Approval For IMM-529

Immuron Limited (IMRN) Presents at Emerging Growth Conference 89 - Slideshow

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target

Reported Monday, Immuron Reports Continued Sales Growth With H1 Global Sales Of AUD$4.2M, Up 5%, Driven By Travelan And ProIBS Launch

Immuron Reports Continued Sales Growth

12 Health Care Stocks Moving In Tuesday's After-Market Session

Immuron (IMRN) Struggles After Announcing Trial Results

Immuron shares are trading lower after topline results from a clinical trial of IMM‑124E did not achieve statistical significance on the primary endpoint.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Why Braze Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Why UiPath Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket